Simulations Plus
Simulations Plus develops and sells modeling and simulation software used by pharmaceutical, biotechnology, and chemical companies to support drug discovery, formulation, and regulatory submissions, along with related consulting and training services. Its platforms help scientists predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties and optimize clinical trial and dosing strategies. The company generates revenue through software licenses, SaaS subscriptions, and scientific consulting engagements.
- Revenue
- $50M - $250M
- Employees
- 51 - 200
- Founded
- 1996
- Headquarters
- Lancaster, United States of America
Simulations Plus customers on Arbolus
Customers who reviewed Simulations Plus
Seniority of Simulations Plus customers
Most people who reviewed Simulations Plus hold Director roles (62%), followed by C-Suite (38%).
- Director 62%
- C-Suite 38%
Customers sample
Employer names and spend open in the full report, along with the other 5 customers.
What 8 Arbolus experts think of Simulations Plus
Overall sentiment: Positive
NPS distribution is 37.5% Promoters, 37.5% Passives, and 25% Detractors, with an average NPS of 7.75 and a score of 12.5. Renewal intent is mixed: 50% Yes, 0% No, 50% Not Sure. Most customers (62.5%) have used the product for more than one year. Key feedback themes include strong regulatory credibility, robust modeling features, and concerns about cost and workflow speed.
Everything 8 customers told us about Simulations Plus.
Employer names, spend, renewal intent and every written answer behind the numbers on this page.
Sentiment
12 Net Promoter Score, from 8 scored reviews- Promoters 3
- Passives 3
- Detractors 2
Praised
- Trusted and Regulator-Accepted Tools
- AI Integration and Automation
Criticised
- Competitive Threat from Lower-Cost Solutions
- Cost and Learning Curve
What Simulations Plus customers say
Trusted and Regulator-Accepted Tools
“I highly recommend Simulations Plus tools, especially the Lixoft suite, as they are among the best options for pharmacometrics and clinical pharmacology, with strong credibility among regulators and partners.”
AI Integration and Automation
“A solution that integrated cleanly with AI assistance, automated repetitive steps, and lowered cost without compromising validation or regulatory acceptance would prompt me to switch.”
Cost and Learning Curve
“Licensing for the Simulations Plus suite adds up, and setup and learning time can slow iteration, especially early in a program when questions change quickly.”
Renewal intent
Plan to renew 50%Plan to renew, by seniority
- 0% 1 answer
- 67% 3 answers
- 9.5/10 Average score from customers who will renew
- 6.5/10 Average score from undecided customers
Report
For people who use Simulations Plus
Do you use Simulations Plus at work?
Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.
- 8 customers of Simulations Plus have already contributed
Takes a few minutes. Your identity stays anonymous.